BIOGEN INC (IDP.DE) Fundamental Analysis & Valuation

FRA:IDP • US09062X1037

160 EUR
+3.3 (+2.11%)
Last: Mar 9, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This IDP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to IDP. IDP was compared to 83 industry peers in the Biotechnology industry. While IDP has a great health rating, its profitability is only average at the moment. IDP is cheap, but on the other hand it scores bad on growth. These ratings could make IDP a good candidate for value investing.


Dividend Valuation Growth Profitability Health

6

1. IDP.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IDP was profitable.
  • IDP had a positive operating cash flow in the past year.
  • Each year in the past 5 years IDP has been profitable.
  • IDP had a positive operating cash flow in each of the past 5 years.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • IDP's Return On Assets of 4.39% is fine compared to the rest of the industry. IDP outperforms 75.90% of its industry peers.
  • IDP has a Return On Equity of 7.08%. This is in the better half of the industry: IDP outperforms 77.11% of its industry peers.
  • IDP's Return On Invested Capital of 8.93% is fine compared to the rest of the industry. IDP outperforms 78.31% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 12.16%.
  • The 3 year average ROIC (8.93%) for IDP is below the current ROIC(8.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • IDP has a Profit Margin of 13.07%. This is in the better half of the industry: IDP outperforms 77.11% of its industry peers.
  • In the last couple of years the Profit Margin of IDP has declined.
  • Looking at the Operating Margin, with a value of 27.94%, IDP belongs to the top of the industry, outperforming 81.93% of the companies in the same industry.
  • IDP's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 75.69%, IDP is in the better half of the industry, outperforming 63.86% of the companies in the same industry.
  • In the last couple of years the Gross Margin of IDP has declined.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IDP.DE Health Analysis

2.1 Basic Checks

  • IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for IDP has been increased compared to 1 year ago.
  • IDP has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, IDP has an improved debt to assets ratio.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • IDP has an Altman-Z score of 3.31. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.31, IDP is doing good in the industry, outperforming 66.27% of the companies in the same industry.
  • IDP has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as IDP would need 3.11 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.11, IDP belongs to the best of the industry, outperforming 83.13% of the companies in the same industry.
  • A Debt/Equity ratio of 0.34 indicates that IDP is not too dependend on debt financing.
  • IDP has a Debt to Equity ratio (0.34) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.31
ROIC/WACC1.06
WACC8.41%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • IDP has a Current Ratio of 2.68. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • IDP has a Current ratio of 2.68. This is comparable to the rest of the industry: IDP outperforms 55.42% of its industry peers.
  • IDP has a Quick Ratio of 2.03. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of IDP (2.03) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. IDP.DE Growth Analysis

3.1 Past

  • The earnings per share for IDP have decreased by -7.16% in the last year.
  • IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.17% yearly.
  • The Revenue has been growing slightly by 2.22% in the past year.
  • Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -5.96% on average per year.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.53% on average over the next years.
  • The Revenue is expected to decrease by -0.48% on average over the next years.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. IDP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.09, the valuation of IDP can be described as correct.
  • Based on the Price/Earnings ratio, IDP is valued cheaper than 91.57% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of IDP to the average of the S&P500 Index (26.46), we can say IDP is valued rather cheaply.
  • A Price/Forward Earnings ratio of 11.50 indicates a reasonable valuation of IDP.
  • Based on the Price/Forward Earnings ratio, IDP is valued cheaply inside the industry as 97.59% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of IDP to the average of the S&P500 Index (24.65), we can say IDP is valued rather cheaply.
Industry RankSector Rank
PE 12.09
Fwd PE 11.5
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaper than 90.36% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 95.18% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.44
EV/EBITDA 8.13
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)2.34
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDP.DE Dividend Analysis

5.1 Amount

  • IDP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDP.DE Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

FRA:IDP (3/9/2026, 7:00:00 PM)

160

+3.3 (+2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners97.35%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap23.48B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target177.03 (10.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)6.89%
PT rev (3m)13.87%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)5.69%
EPS NY rev (3m)4.68%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE 12.09
Fwd PE 11.5
P/S 2.74
P/FCF 13.44
P/OCF 12.31
P/B 1.49
P/tB 10.49
EV/EBITDA 8.13
EPS(TTM)13.23
EY8.27%
EPS(NY)13.91
Fwd EY8.7%
FCF(TTM)11.91
FCFY7.44%
OCF(TTM)13
OCFY8.13%
SpS58.32
BVpS107.66
TBVpS15.26
PEG (NY)2.34
PEG (5Y)N/A
Graham Number179.02
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.31
F-Score4
WACC8.41%
ROIC/WACC1.06
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / IDP.DE FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.


What is the valuation status for IDP stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


What is the profitability of IDP stock?

BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.


What is the financial health of BIOGEN INC (IDP.DE) stock?

The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.


What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to grow by 5.16% in the next year.